Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
about
Glucagon-like peptide analogues for type 2 diabetes mellitusIncretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesPancreatic regulation of glucose homeostasisLixisenatide in type 2 diabetes: latest evidence and clinical usefulnessAdverse Effects of GLP-1 Receptor AgonistsEffects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Lixisenatide: first global approval.Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SLixisenatide: evidence for its potential use in the treatment of type 2 diabetesIncretin therapy--present and future.Injectable Coformulations in DiabetologyNovel Agents for the Treatment of Type 2 Diabetes.Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisComparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsRandomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitusAdding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dogPathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Lixisenatide for type 2 diabetes mellitus.Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.Emerging GLP-1 receptor agonists.Liraglutide: clinical pharmacology and considerations for therapy.Novel GLP-1 receptor agonists for diabetes.GLP-1 based therapies: differential effects on fasting and postprandial glucose.
P2860
Q24235918-D7B67F9A-2823-4B54-863B-7505B88C5412Q24568148-BBB8F1D8-D6D9-42EF-BFF2-CE7B48F0953CQ26766485-95F20F48-5D96-4399-800E-72751DA9D2A8Q26771823-4C7B7E5C-556D-4C79-BD0F-A53A2BED7BFDQ26801346-8D631586-76A7-44E2-9B56-78638A3AF328Q27025423-77C6DBE8-4BC6-4A27-9796-B700FAD9EA76Q28077026-71ABB614-690D-4D48-AE06-414167BCD98AQ30249371-A7D7D580-94EA-426E-BF68-51C41D8A8066Q34337281-6F0EA44A-4FB1-4803-A13C-E9073D457E51Q34640125-6AC2743D-11CF-4736-AB68-0ADADEC7D100Q34726309-977E9203-7713-4B01-BC7D-B86E3DA2FCA6Q35035176-E3163B71-D668-4D29-9383-0E268B705DADQ35192193-5720F43E-DF88-4666-AAA7-ADC8794FB5E1Q35372804-72EB7739-E904-4F3C-977A-3BFEE3BBCD60Q35760283-85B5595B-C247-486E-9F1B-5B7D2496CFAAQ35772586-2D491E5C-60C4-4C4A-9848-28AE86AD00CFQ35910421-CF03D803-5A18-445F-8B3E-31B642842D82Q35976515-2F85CDA1-0BAC-4F9C-A358-186E7EE339BFQ35994230-4DCC0BE6-8E59-4044-9950-1B85759AD0DEQ36011993-80F79638-F420-4D79-A64E-4AFAC04F8619Q36073461-066BDA98-3C75-4118-A1FE-5FCECF248B2FQ36303786-A930CBA0-0B0A-431E-BB37-B1817F748AA4Q36803151-7A5173EA-85FB-418F-9372-77F4E012E8CCQ36972371-274B56E1-A257-4FC3-8C30-8AE473DBE150Q37106467-07721580-52D5-443B-A499-50E95C346D20Q37106537-6E4ADBC6-C363-459A-B8BA-6BA2FB0923DFQ37106572-53E82B0D-22D0-4779-AE8F-9E1494FA6B97Q37119965-8A2E4BDB-3BBE-496F-9AE6-63A14A558838Q37193446-97840878-9A18-48F2-96B4-3B20DDA77364Q37340223-4F7E6CDA-06F8-4799-A970-A8A0E015BBA4Q37410215-91B7014F-6813-4060-BE04-CEA5380E4155Q37439806-90B062CE-1614-4625-A43B-E349B262AA32Q37446672-380FDCDC-4F2D-49C0-9932-0B229C2F6DBFQ37568754-AC4F99F7-987C-448D-ACD2-B5F4B3C76AABQ37851499-38A63A59-0F21-4BDF-B376-0E77F3ABEBB6Q37897817-D13AC9B5-EC11-43C3-A439-7C1583C17B07Q37929744-73776C8F-CC95-4ED7-B811-7D9EE25FDDBAQ37933408-52FFE6A1-7C70-4367-9B59-8B8ED942827FQ37960149-E6795118-BE4E-452E-9A17-1225A46B7DC7Q37974712-C9B1357B-D3DB-455B-8291-10A8DA1F15E0
P2860
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Dose-dependent effects of the ...... lind, placebo-controlled trial
@ast
Dose-dependent effects of the ...... lind, placebo-controlled trial
@en
Dose-dependent effects of the ...... lind, placebo-controlled trial
@nl
type
label
Dose-dependent effects of the ...... lind, placebo-controlled trial
@ast
Dose-dependent effects of the ...... lind, placebo-controlled trial
@en
Dose-dependent effects of the ...... lind, placebo-controlled trial
@nl
prefLabel
Dose-dependent effects of the ...... lind, placebo-controlled trial
@ast
Dose-dependent effects of the ...... lind, placebo-controlled trial
@en
Dose-dependent effects of the ...... lind, placebo-controlled trial
@nl
P2093
P2860
P921
P1433
P1476
Dose-dependent effects of the ...... lind, placebo-controlled trial
@en
P2093
DRI6012 Study Investigators
J Rosenstock
R E Ratner
P2860
P304
P356
10.1111/J.1464-5491.2010.03020.X
P577
2010-09-01T00:00:00Z